Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 1/2 26Phase 1 26Phase 3 7Phase NA 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Squamous Cell Carcinoma of Head and Neck 6Head and Neck Neoplasms 6Lung Neoplasms 4Neoplasm Metastasis 3Melanoma 3Skin Neoplasms 2Recurrence 2Cholangiocarcinoma 2Advanced Solid Tumor 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Squamous NSCLC 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Neoplasms, Squamous Cell 1Neoplasms 1Mouth Neoplasms 1Mesothelioma 1Liver Neoplasms 1Laryngeal Neoplasms 1Laryngeal Diseases 1Klatskin Tumor 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1

Interventions

Gemcitabine 4Cisplatin 2vinflunine 1valrubicin 1pembrolizumab 1enfortumab vedotin 1cabazitaxel 1XRP6258 1Rogaratinib 1Oncolytic Virotherapy 1Mitomycin 1Interferons 1Drug Therapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma, Transitional Cell × pembrolizumab × Clear all
NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Vasgene Therapeutics, Inc

Phase 2/3 Recruiting
700 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡